Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · Delayed Price · USD
19.11
0.59 (3.19%)
At close: Jan 24, 2022 4:00 PM
18.00
-1.11 (-5.81%)
After-hours:Jan 24, 2022 4:05 PM EST
Market Cap1.08B
Revenue (ttm)635,000
Net Income (ttm)-68.18M
Shares Out56.27M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Close18.52
Day's Range17.52 - 20.10
52-Week Range16.00 - 23.16
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About AMLX

Amylyx Pharmaceuticals' mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. We are pursuing commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. We are actively pursuing regulatory approvals of AMX0035 for the treatment of ALS in Canada, the United States and Europe. We h...

IndustryBiotechnology
IPO DateJan 7, 2022
CEOJoshua B. Cohen and Justin B. Klee
Employees34
Stock ExchangeNASDAQ
Ticker SymbolAMLX
Full Company Profile

Financial Performance

Financial Statements

News

Amylyx Pharmaceuticals Announces Launch of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx today announced the launch of its initial public offering of 8,750,000 shares of common stock pursuant to a registration statement on Form S-1.

3 weeks ago - Business Wire